Case Study Investors
Competitive analysis in genomics for a reinsurance company
Client: Global competitive analysis in the genomics space
Strategic Question
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target. Based on our Similarity Score, proprietary to HealthTech Alpha, we selected 50 ventures across the globe with both full and partial product similarity. Based on the profiling of these ventures, we collaborated with our client to select a priority list of 15 ventures and conducted a full Deep Dive analysis of their products, clinical strength and unique selling proposition to build a comparison matrix to further assess their initial investment target. The examination covered Genomics ventures across the globe. Of all ventures we screened 50 and shortlisted a total of 15 companies for selection.
Approach
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target.
Based on our Similarity Score, proprietary to HealthTech Alpha, we selected 50 ventures across the globe with both full and partial product similarity. Based on the profiling of these ventures, we collaborated with our client to select a priority list of 15 ventures and conducted a full Deep Dive analysis of their products, clinical strength and unique selling proposition to build a comparison matrix to further assess their initial investment target.
The examination covered Genomics ventures across the globe. Of all ventures we screened 50 and shortlisted a total of 15 companies for selection.
Strategic Implication
The data, intel and insights developed from this in-depth competitive benchmarking allowed our client to confirm their selection and pursue the investment process for their initial investment target, which was subsequently announced in Q2 2022.
